Recent advances in nonalcoholic fatty liver disease metabolomics

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


The clinical phenotypes of nonalcoholic fatty liver disease (NAFLD) encompass from simple steatosis to nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis or cirrhosis. Liver biopsy has been the standard to diagnose NASH. However, there has been strong need for precise and accurate noninvasive tests because of invasiveness and sampling variability of biopsy. Metabolomics has drawn attention as a promising diagnostic methodology in the field of NAFLD, particularly to unravel metabolic alterations which plays relevant roles in the progression of NASH. There have been numerous metabolomics researches to find new biomarker of NASH in the last decade, fueled by the recent advances in the metabolomics methodology. This review briefly covers recent research advances on the lipidomics, amino acids and bile acid metabolomics regarding continuing attempts to discover relevant biomarkers for NASH.

Original languageEnglish
Pages (from-to)553-559
Number of pages7
JournalClinical and molecular hepatology
Issue number4
StatePublished - Oct 2021


  • Amino acids
  • Bile acids and salts
  • Fatty liver
  • Lipids
  • Phenotype


Dive into the research topics of 'Recent advances in nonalcoholic fatty liver disease metabolomics'. Together they form a unique fingerprint.

Cite this